 Home > Medical News > Latest Medical News > Ascent Pharmaceuticals Orebatinib Receives EU Orphan Drug Qualification Certification

Ascent Pharmaceuticals Orebatinib Receives EU Orphan Drug Qualification Certification

 Last Update: 2021-12-05
 Source: Internet
 Author: User

Tags

lunesta drug class

new treatment tourette's

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On November 22, Ascent Pharmaceuticals announced that the European Commission has recently granted the company a Class 1 new drug Oribatinib (HQP1351) orphan drug designation for the treatment of chronic myeloid leukemia (CML)

CML is a rare hematological malignant disease with an annual incidence rate of 2.

Note: The original text has been deleted

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.